Month: March 2025

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune...

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2024 and provided recent corporate and clinical updates. “We made substantial progress in 2024 advancing our cancer...

Report includes tenfold revenue growth and significant gross margin expansion CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (Nasdaq: NWTG) (“Newton Golf” or the “Company”), a leader in premium golf equipment innovation, today announces financial results for the fourth quarter and full year ended Dec. 31, 2024. The Company delivered record revenue growth, strong margin expansion, and continued operational momentum, supported by strategic product launches, international expansion, and a successful corporate rebranding. HIGHLIGHTSFourth Quarter Revenue of $1,073,000, an 817% increase from $117,000 in Q4 2023. Fourth Quarter Gross Margin expanded to 73%, up from 36% in Q4 2023, driven by enhanced manufacturing efficiencies and an improved product mix. Full-Year Revenue of $3.445 million, representing...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), formerly Silver Spike Investment Corp., a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024 Highlights and Subsequent EventsTotal investment income of $12.7 million Net investment income of $8.0 million, or $0.35 per weighted average share outstanding Investment portfolio of $275.2 million at fair value Net asset value (“NAV”) per share was $13.20 on December 31, 2024 As previously announced, on October 1, 2024, the Company acquired a portfolio of loans (the “Loan Portfolio”) from Chicago Atlantic Loan Portfolio, LLC (“CALP”) in exchange for newly issued shares...

      – Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 – Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. “2025 is positioned to be a transformational year for Unicycive, with the near-term potential for FDA approval and commercial launch of oxylanthanum carbonate (OLC),” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive....

– Fourth quarter and full-year 2024 total revenue of $2.0 million and $11.0 million, respectively.– Fourth quarter and full-year 2024 CORE EBITDA of $3.3 million and $3.9 million, respectively.– Held 165.8 Bitcoin on February 28, 2025 valued at approximately $14.4 million, as of March 26, 2025 TAMPA, Fla., March 31, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today reported financial results for the three months and full year ended December 31, 2024. Q4’24 Financial HighlightsAll variances are compared with prior year unless stated otherwise:Mined 21.7 Bitcoin at an average price of approximately $83,000, generating total revenue of approximately $2.0 million. The year-over-year decrease in revenue...

Fourth Quarter Highlights and Recent DevelopmentsFourth quarter revenue of $13.2 million, at the high end of our prior target Entered into 5-gigawatt supply arrangement with Recurrent Energy Awarded 330+ megawatt project in Australia from GPG Naturgy Awarded 280-megawatt project in U.S. from Rosendin Appointed industry veteran Kent James as U.S. Chief Commercial Officer Received additional $3.2 million earn-out on prior investment post quarter end Announced upsizing of promissory note offering for up to additional $10-$15 mil. to close in Q2AUSTIN, Texas, March 31, 2025 (GLOBE NEWSWIRE) —  FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, today announced financial results for the fourth quarter that ended December 31, 2024. “In addition to reporting favorable quarterly results relative to our targets,...